After a series of failure to get many of its drugs get patent protection, Sanofi SA has finally tasted success. Its multiple sclerosis drug known as Aubagio has got green signal from the US regulators.

Experts were of the view that though the drug is a bit less effective than other available drugs, it has few side effects, which might make it a big hit among newly diagnosed patients. Russell Katz, who is heading the Neurology Products department at the Food and Drug Administration, was of the view that they have seen a potential in the drug.

They noticed that people, who took the pill, were 30% at lower risk to relapse than people, who took placebo. Meanwhile, Sanofi officials are quite busy for launching their pill in the US market. Giving further information on the same, the officials were of the view that the pill will be launched in next few weeks.

If to look at the market scenario then it will be found that a lot of struggle is needed for Aubagio to make a niche place in the market. There is a reason for the same as Gilenya and BG-12 are the two drugs that rule the market when it comes to treatment of multiple sclerosis.